Patents by Inventor Muhamed-Kheir Taha

Muhamed-Kheir Taha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11618781
    Abstract: The present invention is directed to polyclonal antibodies, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X in biological fluids without culture. The invention also concerns said polyclonal antibodies in different diagnostic tests and methods, in order to detect NmX. The invention discloses also a rapid diagnostic test for detecting NmX in a biological fluid, as well as a method for obtaining polyclonal antibodies useful for detecting NmX in biological fluids such as cerebrospinal fluid, serum and urine.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: April 4, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Muhamed-Kheir Taha, Alain Agnememel, Francois Traincard, Laurence Mulard
  • Publication number: 20210095009
    Abstract: The present invention is directed to polyclonal antibodies, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X in biological fluids without culture. The invention also concerns said polyclonal antibodies in different diagnostic tests and methods, in order to detect NmX.
    Type: Application
    Filed: September 30, 2020
    Publication date: April 1, 2021
    Inventors: Muhamed-Kheir TAHA, Alain AGNEMEMEL, Francois TRAINCARD, Laurence MULARD
  • Patent number: 10822398
    Abstract: Polyclonal antibodies specific for serogroup X of N. meningitidis and uses thereof in diagnosis. The present invention is directed to polyclonal antibodies, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X in biological fluids without culture. The invention also concerns said polyclonal antibodies in different diagnostic tests and methods, in order to detect Nm X. The invention discloses also a rapid diagnostic test for detecting NmX in a biological fluid, as well as a method for obtaining polyclonal antibodies useful for detecting NmX in biological fluids such as cerebrospinal fluid, serum and urine.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: November 3, 2020
    Assignee: INSTITUT PASTEUR
    Inventors: Muhamed-Kheir Taha, Alain Agnememel, Francois Traincard, Laurence Mulard
  • Patent number: 10613085
    Abstract: The present invention is directed to monoclonal antibodies and antigen-binding portions thereof, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies or portions thereof are characterized by the sequences of the 6 CDR of the variable regions of the heavy and light chains. These antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X especially in a biological sample without purification of the capsular polysaccharides. The invention also concerns said monoclonal antibodiesor adequate portions thereofin different diagnostic tests and methods, in order to detect NmX. The invention discloses also a rapid diagnostic test for detecting NmX in a biological fluid.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: April 7, 2020
    Assignee: INSTITUT PASTEUR
    Inventors: Muhamed-Kheir Taha, Alain Agnememel
  • Patent number: 10376573
    Abstract: A method for immunizing a subject against serogroup X meningococcus by administering a vaccine comprising one, two or all three of: (i) a meningococcal fHbp antigen; (ii) a meningococcal NHBA antigen; and/or (iii) a meningococcal NadA antigen. The vaccine may also include meningococcal outer membrane vesicles.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: August 13, 2019
    Assignees: GlaxoSmithKline Biologicals SA, Institut Pasteur
    Inventors: Mariagrazia Pizza, Peter Dull, Marzia Monica Giuliani, Muhamed-Kheir Taha, Eva Hong, Ala-Eddine Deghmane
  • Publication number: 20180180610
    Abstract: The present invention is directed to monoclonal antibodies and antigen-binding portions thereof, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies or portions thereof are characterized by the sequences of the 6 CDR of the variable regions of the heavy and light chains. These antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X especially in a biological sample without purification of the capsular polysaccharides. The invention also concerns said monoclonal antibodiesor adequate portions thereofin different diagnostic tests and methods, in order to detect NmX. The invention discloses also a rapid diagnostic test for detecting NmX in a biological fluid.
    Type: Application
    Filed: June 8, 2016
    Publication date: June 28, 2018
    Inventors: Muhamed-Kheir TAHA, Alain AGNEMEMEL
  • Publication number: 20170334975
    Abstract: Polyclonal antibodies specific for serogroup X of N. meningitidis and uses thereof in diagnosis. The present invention is directed to polyclonal antibodies, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X in biological fluids without culture. The invention also concerns said polyclonal antibodies in different diagnostic tests and methods, in order to detect Nm X. The invention discloses also a rapid diagnostic test for detecting NmX in a biological fluid, as well as a method for obtaining polyclonal antibodies useful for detecting NmX in biological fluids such as cerebrospinal fluid, serum and urine.
    Type: Application
    Filed: November 17, 2015
    Publication date: November 23, 2017
    Inventors: Muhamed-Kheir TAHA, Alain AGNEMEMEL, Francois TRAINCARD, Laurence MULARD
  • Publication number: 20160166674
    Abstract: A method for immunising a subject against serogroup X meningococcus by administering a vaccine comprising one, two or all three of: (i) a meningococcal fHbp antigen; (ii) a meningococcal NHBA antigen; and/or (iii) a meningococcal NadA antigen. The vaccine may also include meningococcal outer membrane vesicles.
    Type: Application
    Filed: June 14, 2013
    Publication date: June 16, 2016
    Inventors: Mariagrazia PIZZA, Peter DULL, Marzia Monica GIULIANI, Muhamed-Kheir TAHA, Eva HONG, Ala-Eddine DEGHMANE
  • Publication number: 20090053237
    Abstract: The present invention is drawn to a penicillin-binding protein expressed by Neisseria meningitidis, or a fragment, or a variant, or a variant fragment thereof, or nucleic acids encoding them, or antibodies or antibody fragments directed against them, as medicaments or in pharmaceutical compositions. The invention is also directed to the use of penicillin-binding proteins expressed by Neisseria meningitidis, or nucleic acids encoding them, or antibodies directed against them for the prophylactic and/or therapeutic immunotherapy of mammals, preferably human beings, against infection by Neisseria meningitidis and/or by a bacterial strain expressing a variant of a Neisseria meningitidis penicillin-binding protein.
    Type: Application
    Filed: May 22, 2006
    Publication date: February 26, 2009
    Applicant: INSTITUT PASTEUR
    Inventors: Maria Leticia Zarantonelli, Aude Antignac, Jean-Michel Alonso, Muhamed-Kheir Taha, Faridabano Nato